Tonix Pharmaceuticals Presents Strong Post-Hoc Phase 3 Data for FDA-Approved Fibromyalgia Drug TONMYA™

summarizeSummary

Tonix Pharmaceuticals announced positive post-hoc Phase 3 data presentations for its FDA-approved fibromyalgia drug, TONMYA™, highlighting rapid pain relief and a favorable benefit-risk profile.

check_boxKey Events

• Rapid Pain Relief Demonstrated

  Post-hoc analysis of the RESILIENT Phase 3 trial showed TONMYA™ provided rapid pain reduction in fibromyalgia patients, with improvements observed as early as Day 2 and statistically significant relief over 14 weeks.

• Favorable Benefit-Risk Profile

  A pooled analysis of Phase 3 trials (RELIEF and RESILIENT) indicated a Likelihood to be Helped or Harmed (LHH) of 3.7, suggesting a nearly four-fold greater likelihood of clinical benefit than adverse event-related discontinuation.

• Reinforces Commercial Potential

  These presentations provide strong supporting data for TONMYA™, an FDA-approved drug launched in November 2025, which is the first new treatment for fibromyalgia in over 15 years.

auto_awesomeAnalysis

This filing details positive post-hoc analyses of Phase 3 data for TONMYA™, an FDA-approved drug for fibromyalgia that was launched in November 2025. The data reinforces TONMYA's efficacy, showing rapid pain relief as early as Day 2 and a favorable benefit-risk profile. This information strengthens the commercial narrative for TONMYA, potentially boosting physician adoption and market penetration for a product positioned as the first new fibromyalgia treatment in over 15 years. Investors should view this as positive validation for a key revenue driver.